SERMORELIN
Sermorelin is a 29-amino-acid fragment of human growth hormone-releasing hormone (GHRH) that stimulates the pituitary to release growth hormone. Unlike many compounds in today's peptide conversation, sermorelin has a substantial human history and was once marketed as the FDA-approved drug Geref. The important question is how much that older clinical story tells us about today's adult anti-aging, recovery and body-composition claims.
Sermorelin signals your pituitary to release more of your own growth hormone, which is why it has become popular for sleep, recovery, body composition and healthy-aging goals.
Modern claims need context.
Human evidence clearly supports GH stimulation, and historical pediatric treatment evidence exists. Today's broader adult optimization narrative is a different question.
A short version of the body's own GH-releasing signal.
Sermorelin is the amidated 1–29 fragment of human GHRH and retains the biological activity needed to stimulate GH secretion from the anterior pituitary.
That puts sermorelin in a different branch of the GH-axis conversation from ghrelin-receptor agonists such as ipamorelin. It also differs from longer-acting GHRH analogues such as CJC-1295: sermorelin has a much shorter pharmacologic action.
The GH response is not speculative.
Controlled human studies have repeatedly shown that GHRH(1-29)-NH2 produces a measurable GH response. A randomized dose-response study in adult men found significant GH responses to 10- and 100-microgram intravenous doses compared with saline.
Historically, sermorelin was used both diagnostically and therapeutically. A 1999 review concluded that intravenous and subcutaneous sermorelin specifically stimulated pituitary GH secretion and summarized limited evidence of increased height velocity in some prepubertal children with idiopathic growth-hormone deficiency.
Interesting human data—without being a modern longevity trial.
Older GHRH-analogue research helps explain why sermorelin became interesting to longevity medicine.
In a small randomized placebo-controlled study of 19 adults aged 55–71, nightly administration of a closely related [Nle27]GHRH(1-29)-NH2 analog for 16 weeks increased nocturnal GH and IGF-1. The study also reported increased lean body mass and insulin sensitivity in men, but not women; sleep quality was unaffected in both sexes.
What people are actually reporting.
Commonly discussed goals include sleep quality, recovery, body composition and maintaining GH-axis activity with age. Individual accounts vary and are not a reliable measure of efficacy.
Reported effects cannot be attributed confidently to sermorelin when people also change exercise, nutrition, sleep habits or other therapies. Its historical pediatric indication does not validate modern adult optimization claims.
The modern use case has moved far beyond pediatrics.
Today, sermorelin is discussed primarily in adult optimization contexts—sleep, recovery, body composition, training, GH support and healthy aging.
That shift is scientifically interesting because the community is applying a well-established endocrine mechanism to a very different population and set of desired outcomes than those behind sermorelin's original approval.
Where the old evidence meets the new story.
CONTEXT-DEPENDENT
The gap is relatively narrow if the claim is simply that sermorelin stimulates pituitary GH release. It becomes much wider when that established hormonal effect is translated into better sleep, faster recovery, improved body composition, more muscle or slower aging in otherwise healthy adults.
Modern use looks different from the original clinical story.
Current peptide and longevity communities most often discuss sermorelin as a bedtime GH-axis intervention rather than for the pediatric growth-failure indication associated with the former FDA-approved Geref product.
Amounts vary by clinic and community source. The modern adult pattern should not be confused with historical labeled use of Geref or interpreted as an FDA-established anti-aging dose.
Sermorelin has established human GH-stimulating biology and a history of FDA-approved pediatric use, but no FDA-established adult anti-aging or body-composition protocol. Modern community use extends beyond the population and outcomes that supported its historical clinical role.
Previously approved. No longer marketed as Geref.
FDA records show that Geref (sermorelin acetate) was approved in 1990 as a diagnostic agent for evaluating pituitary GH secretion and in 1997 for treatment of idiopathic growth-hormone deficiency in children with growth failure.
The sponsor discontinued the products and requested withdrawal of the NDAs; FDA withdrew the approvals effective June 18, 2009. In 2013, FDA formally determined that the Geref products had not been withdrawn for reasons of safety or effectiveness.
Primary evidence behind the profile.
| Evidence | Design | What it adds | What it cannot prove |
|---|---|---|---|
| 1994 · PMID 7921207 | Randomized human dose-response study | Demonstrated significant GH responses to GHRH(1-29)-NH2 in adult men. | Does not establish modern optimization outcomes. |
| 1999 · PMID 18031173 | Clinical review | Summarized diagnostic use and pediatric growth-deficiency treatment experience with sermorelin. | Does not establish adult longevity efficacy. |
| 1997 · PMID 9141536 | Small randomized placebo-controlled study of a modified GHRH(1-29) analog | Human aging-related GH/IGF-1 and body-composition signal. | Not the same molecule as unmodified sermorelin; small study; mixed sex-specific outcomes. |
| FDA · Geref history | Regulatory record | Documents historical approvals, discontinuation and FDA's finding that withdrawal was not for safety/effectiveness reasons. | Does not create a current approved adult optimization indication. |
Read deeper.
Compare the GH-axis story.
CJC-1295
A longer-acting GHRH analogue with sustained human GH/IGF-1 target engagement.
Ipamorelin
A ghrelin-receptor secretagogue that reaches the GH axis through a different pathway.
Tesamorelin
A GHRH analogue with a current FDA-approved indication and randomized human outcome data.
What the evidence actually shows.
Historical approval is not current approval
Sermorelin was marketed as Geref for specific pediatric growth-hormone deficiency and diagnostic uses. The FDA withdrew the original product approvals in 2009 after discontinuation, and later determined the products were not withdrawn for reasons of safety or effectiveness. This history does not establish FDA approval of currently marketed compounded sermorelin or prove adult sleep, muscle, or longevity benefits.
Verification source: FDA Federal Register determination, March 4, 2013.
Community Protocol Signal describes unvalidated practices and is not a clinical dosing recommendation.